Company intelligence / Profile preview

Pan Cancer T

Ownership: Private
Development stage: Preclinical

Overview

Lead candidate PCT1:CO-STIM has demonstrated preclinical proof-of-concept in triple-negative breast cancer. The company is finalizing the preclinical data package and remaining CMC work, aiming to advance to Phase Ib/IIa clinical studies in H2 2026.

Therapeutic areas: Oncology
Modalities: TCR-T cell therapyAdoptive T cell therapy
Industry: Biotech

Drug pipeline

2 assets

PCT3

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pan Cancer T.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pan Cancer T.

Explore the full profile